Macular Degeneration

A leading cause of vision loss affecting the central part of the retina

What is Macular Degeneration?

Age-related macular degeneration (AMD) is a deterioration of the retina and choroid that leads to substantial loss in visual acuity. It affects the macula, the small central area of the retina responsible for detailed color vision. AMD is a leading cause of vision loss in adults over 50.

Types of Macular Degeneration

Dry AMD (85% of cases)

Characterized by drusen deposits and can progress to geographic atrophy. This is the more common, slower-progressing form of the disease.

New Treatments Available

Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) are now available for geographic atrophy

Wet AMD (15% of cases)

Features choroidal neovascularization where abnormal blood vessels grow beneath the retina. Less common but more serious form that can cause rapid vision loss.

Excellent Treatment Success

Anti-VEGF treatment has dramatically improved outcomes since 2005

Understanding the Disease

Risk Factors

  • • Age (primary risk factor - older patients have greater risk)
  • • Family history of AMD
  • • Female gender
  • • Caucasian or European descent
  • • Smoking history
  • • Cardiovascular disease

Symptoms by Stage

Early Stages

Often asymptomatic - regular eye exams are crucial for detection

Intermediate Dry AMD

Difficulty reading in dim light, decreased color intensity, early distortion

Advanced Dry AMD (Geographic Atrophy)

Marked distortion of straight lines, difficulty with night driving, gradual central vision loss, dark/blurry central areas

Wet AMD

Sudden/gradual visual acuity decrease, central blind spots, distortion of straight lines

Diagnostic Methods

Comprehensive Dilated Eye Exam

Complete retinal evaluation

OCT Imaging

Detailed cross-sectional images

Fluorescein Angiography

For wet AMD evaluation

Amsler Grid Testing

Detects distortion and changes

Treatment Options

Wet AMD Treatment

Anti-VEGF intravitreal injections (primary treatment) with excellent outcomes since 2005

Treatment regimens include "treat and extend" or "pro re nata" protocols

Advanced Dry AMD

Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) for geographic atrophy

New FDA-approved treatments to slow progression

Intermediate Dry AMD

AREDS nutritional supplements

Specific vitamins and minerals to slow progression

Prevention & Management

  • • AREDS nutritional supplements for intermediate stages
  • • Regular eye examinations
  • • Amsler grid monitoring at home
  • • Lifestyle modifications (diet, smoking cessation)
  • • UV protection
  • • Control blood pressure and cholesterol

Home Monitoring Tool

Use the Amsler grid test at home to monitor your vision between appointments and catch changes early.

Access Amsler Grid Test

Excellent Prognosis with Modern Treatment

Wet AMD: Anti-VEGF treatment has dramatically improved outcomes since 2005, with patients maintaining central vision for reading, driving, and face recognition.

Dry AMD: Variable progression, with new treatments now available to slow geographic atrophy progression.